

## Highlights of This Issue 6225

### SPECIAL FEATURES


#### CCR Translations

- 6227** Paracrine Network: Another Step in the Complexity of Resistance to EGFR Blockade?  
Ramon Salazar, Gabriel Capellà, and Josep Tabernero  
*See related article, p. 6429*
- 6230** Galectin-1 and Immune Suppression during Radiotherapy  
James W. Welsh, Steven N. Seyedin, Maria Angelica Cortez, Amit Maity, and Stephen M. Hahn

#### CCR New Strategies

- 6233** New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine  
Ivana Gojo and Judith E. Karp
- 6242** New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T<sub>1a,b</sub>N<sub>0</sub>M<sub>0</sub> Tumors  
Amir Sonnenblick, Debora Fumagalli, Hatem A. Azim Jr, Christos Sotiriou, and Martine Piccart

#### Molecular Pathways

- 6247** Molecular Pathways: microRNAs, Cancer Cells, and Microenvironment  
 Ioana Berindan-Neagoe and George A. Calin


#### Perspectives

- 6254** Modernizing the Diagnostic and Decision-Making Pathway for Prostate Cancer  
Thomas J. Polascik, Niccolo' M. Passoni, Arnauld Villers, and Peter L. Choyke

#### Review

- 6258**  Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects  
Scott J. Antonia, James Larkin, and Paolo A. Ascierto

#### CANCER THERAPY: CLINICAL

- 6269** Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens  
Won Kim, Li Zhang, John H. Wilton, Gerald Fetterly, James L. Mohler, Vivian Weinberg, Allison Morse, Russell Z. Szmulewitz, Terence W. Friedlander, Lawrence Fong, Amy M. Lin, Andrea L. Harzstark, Arturo Molina, Eric J. Small, and Charles J. Ryan
- 6277** Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer  
Stephen V. Liu, Denice D. Tsao-Wei, Shigang Xiong, Susan Groshen, Tanya B. Dorff, David I. Quinn, Yu-Chong Tai, Juergen Engel, Debra Hawes, Andrew V. Schally, and Jacek K. Pinski
- 6284** A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors  
L. Rhoda Molife, Emma Jane Dean, Montserrat Blanco-Codesido, Matthew G. Krebs, Andre T. Brunetto, Alastair Peter Greystoke, Gennaro Daniele, Lucy Lee, Galina Kuznetsov, Khin Than Myint, Karen Wood, Begoña de las Heras, and Malcolm Richard Ranson
- 6295**  A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors  
David C. Smith, Peter D. Eisenberg, Georgy Manikhas, Rashmi Chugh, Matthew A. Gubens, Robert J. Stagg, Ann M. Kapoun, Lu Xu, Jakob Dupont, and Branimir Sikic

# Table of Contents

- 6304** A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma  
Wolfgang Wick, Harald Fricke, Klaus Junge, Grigory Kobayakov, Tobias Martens, Oliver Heese, Benedikt Wiestler, Maximilian G. Schliesser, Andreas von Deimling, Josef Pichler, Elena Vetlova, Inga Harting, Jürgen Debus, Christian Hartmann, Claudia Kunz, Michael Platten, Martin Bendszus, and Stephanie E. Combs

## PERSONALIZED MEDICINE AND IMAGING

- 6314** Screening for Cardiac Dysfunction in Anthracycline-Exposed Childhood Cancer Survivors  
Saro H. Armenian, Sarah K. Gelehrter, Tabitha Vase, Rajkumar Venkatramani, Wendy Landier, Karla D. Wilson, Claudia Herrera, Leah Reichman, John-David Menteer, Leo Mascarenhas, David R. Freyer, Kalyanasundaram Venkataraman, and Smita Bhatia
- 6324** MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer  
Xiangnan Du, Benjamin C. Lin, Qian-Rena Wang, Hao Li, Ellen Ingalla, Janet Tien, Isabelle Rooney, Avi Ashkenazi, Elicia Penuel, and Jing Qing
- 6336** Analysis of 1,115 Patients Tested for *MET* Amplification and Therapy Response in the MD Anderson Phase I Clinic  
Denis L.F. Jardim, Chad Tang, Debora De Melo Gagliato, Gerald S. Falchook, Kenneth Hess, Filip Janku, Siqing Fu, Jennifer J. Wheler, Ralph G. Zinner, Aung Naing, Apostolia M. Tsimberidou, Vijaykumar Holla, Marylin M. Li, Sinchita Roy-Chowdhuri, Raja Luthra, Ravi Salgia, Razelle Kurzrock, Funda Meric-Bernstam, and David S. Hong
- 6346** Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer  
Theodora Katsila, Mercè Juliachs, Josep Gregori, Teresa Macarulla, Laura Villarreal, Alberto Bardelli, Chris Torrance, Elena Elez, Josep Tabernero, and Josep Villanueva

- 6357** DNA Methylation Status of Key Cell-Cycle Regulators Such as *CDKNA2/p16* and *CCNA1* Correlates with Treatment Response to Doxorubicin and 5-Fluorouracil in Locally Advanced Breast Tumors  
Jovana Klajic, Florence Busato, Hege Edvardsen, Nizar Touleimat, Thomas Fleischer, Ida Bukholm, Anne-Lise Børresen-Dale, Per Eystein Lønning, Jörg Tost, and Vessela N. Kristensen

- 6367** Applications of ImmunoPET: Using <sup>124</sup>I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer  
Scott M. Knowles, Richard Tavaré, Kirstin A. Zettlitz, Matthew M. Rochefort, Felix B. Salazar, Ziyue Karen Jiang, Robert E. Reiter, and Anna M. Wu

- 6379** A Tissue Biomarker-Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02  
Alan Pollack, James J. Dignam, Dayssy A. Diaz, Qian Wu, Radka Stoyanova, Kyoungwha Bae, Adam P. Dicker, Howard Sandler, Gerald E. Hanks, and Felix Y. Feng


- 6389** *In Vivo* Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [<sup>18</sup>F]HX4 and [<sup>18</sup>F]FDG-PET/CT Imaging  
Catharina M.L. Zegers, Wouter van Elmpst, Bart Reymen, Aniek J.G. Even, Esther G.C. Troost, Michel C. Öllers, Frank J.P. Hoebbers, Ruud M.A. Houben, Jonas Eriksson, Albert D. Windhorst, Felix M. Mottaghy, Dirk De Ruysscher, and Philippe Lambin


- 6398** Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial  
Sara Galimberti, Stefano Luminari, Elena Ciabatti, Susanna Grassi, Francesca Guerrini, Alessandra Dondi, Luigi Marcheselli, Marco Ladetto, Pier Paolo Piccaluga, Anna Gazzola, Claudia Mannu, Luigia Monitillo, Barbara Mantoan, Ilaria Del Giudice, Irene Della Starza, Marzia Cavalli, Luca Arcaini, Alessandra Tucci, Giuseppe Alberto Palumbo, Luigi Rigacci, Alessandro Pulsoni, Umberto Vitolo, Carola Boccomini, Daniele Vallisa, Giovanni Bertoldero, Gianluca Gaidano, Pellegrino Musto, Mario Petrini, and Massimo Federico



# Table of Contents

## CANCER THERAPY: PRECLINICAL

- 6406** Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer  
Julius Chapiro, Surojit Sur, Lynn Jeanette Savic, Shanmugasundaram Ganapathy-Kanniappan, Juvenal Reyes, Rafael Duran, Sivarajan Chettiar Thiruganasambandam, Cassandra Rae Moats, MingDe Lin, Weibo Luo, Phuoc T. Tran, Joseph M. Herman, Gregg L. Semenza, Andrew J. Ewald, Bert Vogelstein, and Jean-François Geschwind
- 6418** Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma   
Huiping Gao, Kesang Li, Hong Tu, Xiaorong Pan, Hua Jiang, Bizhi Shi, Juan Kong, Hongyang Wang, Shengli Yang, Jianren Gu, and Zonghai Li
- 6429** TGF $\alpha$  and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells  
Sebastijan Hobor, Beth O. Van Emburgh, Emily Crowley, Sandra Misale, Federica Di Nicolantonio, and Alberto Bardelli  
*See related commentary, p. 6227*
- 6439** iNOS Expression in CD4<sup>+</sup> T Cells Limits Treg Induction by Repressing TGF $\beta$ 1: Combined iNOS Inhibition and Treg Depletion Unmask Endogenous Antitumor Immunity  
Padmini Jayaraman, Matthew G. Alfarano, Peter F. Svider, Falguni Parikh, Geming Lu, Sarah Kidwai, Huabao Xiong, and Andrew G. Sikora
- 6452** Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis  
Marika Karikoski, Fumiko Marttila-Ichihara, Kati Elima, Pia Rantakari, Maija Hollmén, Tiina Kelkka, Heidi Gerke, Ville Huovinen, Heikki Irjala, Rikard Holmdahl, Marko Salmi, and Sirpa Jalkanen
- 6465** Dual Disruption of DNA Repair and Telomere Maintenance for the Treatment of Head and Neck Cancer  
Shayanne A. Lajud, Danish A. Nagda, Taku Yamashita, Jun Zheng, Nobuaki Tanaka, Waleed M. Abuzeid, Alyssa Civantos, Orysia Bezpalko, Bert W. O'Malley Jr, and Daqing Li

- 6479** Doxorubicin Synergizes with 34,5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer  
Chelsea Bolyard, Ji Young Yoo, Pin-Yi Wang, Uksha Saini, Kellie S. Rath, Timothy P. Cripe, Jianying Zhang, Karuppaiyah Selvendiran, and Balveen Kaur
- 6495** Zinc Finger Nucleases Targeting the Human Papillomavirus E7 Oncogene Induce E7 Disruption and a Transformed Phenotype in HPV16/18-Positive Cervical Cancer Cells  
Wencheng Ding, Zheng Hu, Da Zhu, Xiaohui Jiang, Lan Yu, Xiaoli Wang, Changlin Zhang, Liming Wang, Teng Ji, Kezhen Li, Dan He, Xi Xia, Dan Liu, Jianfeng Zhou, Ding Ma, and Hui Wang
- 6504** The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer  
Fang Fang, Joanne Munck, Jessica Tang, Pietro Taverna, Yinu Wang, David F.B. Miller, Jay Pilrose, Gavin Choy, Mohammad Azab, Katherine S. Pawelczak, Pamela VanderVere-Carozza, Michael Wagner, John Lyons, Daniela Matei, John J. Turchi, and Kenneth P. Nephew
- 6517** Dual HER2 Targeting Impedes Growth of HER2 Gene-Amplified Uterine Serous Carcinoma Xenografts   
Jolijn W. Groeneweg, Silvia F. Hernandez, Virginia F. Byron, Celeste M. DiGloria, Hector Lopez, Vanessa Scialabba, Minji Kim, Ling Zhang, Darrell R. Borger, Rosemary Tambouret, Rosemary Foster, Bo R. Rueda, and Whitfield B. Crowdon

## BIOLOGY OF HUMAN TUMORS

- 6529** Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery  
Xinqun Li, Mark A. Truty, Ya'an Kang, Xavier Chopin-Laly, Ran Zhang, David Roife, Deyali Chatterjee, E. Lin, Ryan M. Thomas, Huamin Wang, Matthew H. Katz, and Jason B. Fleming

# Table of Contents

- 6541** **RhoB Determines Tumor Aggressiveness in a Murine EGFR<sup>L858R</sup>-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer**  
Olivier Calvayrac, Anne Pradines, Isabelle Raymond-Letron, Isabelle Rouquette, Emilie Bousquet, Valérie Lauwers-Cances, Thomas Filleron, Jacques Cadranet, Michèle Beau-Faller, Anne Casanova, Julie Milia, Gilles Favre, and Julien Mazières
- 6551** **Identification of Recurrent *FGFR3-TACC3* Fusion Oncogenes from Lung Adenocarcinoma**  
Marzia Capelletti, Michael E. Dodge, Dalia Ercan, Peter S. Hammerman, Seung-Il Park, Jhingook Kim, Hidefumi Sasaki, David M. Jablons, Doron Lipson, Lauren Young, Phil J. Stephens, Vincent A. Miller, Neal I. Lindeman, Kiara J. Munir, William G. Richards, and Pasi A. Jänne
- 6559** **miR-154\* and miR-379 in the DLK1-DIO3 MicroRNA Mega-Cluster Regulate Epithelial to Mesenchymal Transition and Bone Metastasis of Prostate Cancer**  
Murali Gururajan, Sajni Josson, Gina Chia-Yi Chu, Chia-Lun Lu, Yi-Tsung Lu, Christopher L. Haga, Haiyen E. Zhou, Chunyan Liu, Jake Lichterman, Peng Duan, Edwin M. Posadas, and Leland W.K. Chung
- 6570** **Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications**  
Yoshitsugu Mitani, Pulivarthi H. Rao, Sankar N. Maity, Yu-Chen Lee, Renata Ferrarotto, Julian C. Post, Lisa Licitra, Scott M. Lippman, Merrill S. Kies, Randal S. Weber, Carlos Caulin, Sue-Hwa Lin, and Adel K. El-Naggar
- 6582** **Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma**  
Curtis R. Pickering, Jane H. Zhou, J. Jack Lee, Jennifer A. Drummond, S. Andrew Peng, Rami E. Saade, Kenneth Y. Tsai, Jonathan L. Curry, Michael T. Tetzlaff, Stephen Y. Lai, Jun Yu, Donna M. Muzny, Harshavardhan Doddapaneni, Eve Shinbrot, Kyle R. Covington, Jianhua Zhang, Sahil Seth, Carlos Caulin, Gary L. Clayman, Adel K. El-Naggar, Richard A. Gibbs, Randal S. Weber, Jeffrey N. Myers, David A. Wheeler, and Mitchell J. Frederick
- 6593** **Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression**  
Antje Sucker, Fang Zhao, Birgit Real, Christina Heeke, Nicola Bielefeld, Stefan Maßen, Susanne Horn, Iris Moll, Raffaella Maltaner, Peter A. Horn, Bastian Schilling, Francesco Sabbatino, Volker Lennerz, Matthias Kloor, Soldano Ferrone, Dirk Schadendorf, Christine S. Falk, Klaus Griewank, and Annette Paschen
- 6605** **Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of *UNC5C* and Prognostic Importance of DNA Repair Gene Mutations on Survival**  
 Kai Lee Yap, Kazuma Kiyotani, Kenji Tamura, Tatjana Antic, Miran Jang, Magdeline Montoya, Alexa Campanile, Poh Yin Yew, Cory Ganshert, Tomoaki Fujioka, Gary D. Steinberg, Peter H. O'Donnell, and Yusuke Nakamura
- 6618** **Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and *TP53*-Mutant Tumors and Identifies *NRAS* as an Oncogenic Driver**  
Catherine Emmanuel, Yoke-Eng Chiew, Joshy George, Dariush Etemadmoghadam, Michael S. Anglesio, Raghwa Sharma, Peter Russell, Catherine Kennedy, Sian Fereday, Jillian Hung, Laura Galletta, for the Australian Ovarian Cancer Study (AOCS), Russell Hogg, Gerard V. Wain, Alison Brand, Rosemary Balleine, Laura MacConaill, Emanuele Palescandolo, Sally M. Hunter, Ian Campbell, Alexander Dobrovic, Stephen Q. Wong, Hongdo Do, Christine L. Clarke, Paul R. Harnett, David D.L. Bowtell, and Anna deFazio

## LETTERS TO THE EDITOR

- 6631** **Melanoma BRAF Fusions—Letter**  
Thomas Botton, Iwei Yeh, and Boris C. Bastian
- 6632** **Melanoma BRAF Fusions—Response**  
Katherine E. Hutchinson, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Jeffrey A. Sosman, and William Pao
- 6633** **Prognostic Serum Cytokines in Classical Hodgkin Lymphoma—Letter**  
Oliver Coutelle, Hildegard Büning, Annette Plütschow, Michael Fuchs, Laura Escalona-Espinosa, Andreas Engert, and Ulrich Hacker
- 6634** **Acknowledgment to Reviewers**




AC icon indicates Author Choice



CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)




# Table of Contents

---

## ABOUT THE COVER

The cover shows a section of B16 melanoma. Immunohistochemical staining shows aberrant Clever-1 expression on tumor vasculature. For details, see the article by Karikoski and colleagues on page 6452 of this issue.



# Clinical Cancer Research

**20 (24)**

*Clin Cancer Res* 2014;20:6225-6642.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/20/24>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/24>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.